Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

Journal of the National Cancer Institute

Volumn 101, Issue 11, 2009, Pages 782-792

  Jagu, Subhashini ^a   Karanam, Balasubramanyam ^a   Gambhira, Ratish ^a   Chivukula, Sudha V ^c   Chaganti, Revathi J ^c   Lowy, Douglas R ^d   Schiller, John T ^d   Roden, Richard B S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Hantha Biotechnics Ltd   (India)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CONCATENATED MULTITYPE L2 FUSION PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE; ANTISERUM; CAPSID PROTEIN; EPITOPE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 45; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANALYSIS OF VARIANCE; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; METHODOLOGY; RABBIT; SERODIAGNOSIS; TIME; VIRION; VIROLOGY; VIRUS INFECTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNE SERA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RABBITS; TIME FACTORS; VIRION;

EID: 67449084618     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp106     Document Type: Article

References (60)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348 (6): 518-527.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189 (1): 12-19.
3. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992; 89 (24): 12180-12184.
4. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993; 67 (4): 1936-1944.
5. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol. 1999; 73 (11): 9609-9613.
6. Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol. 1994; 75 (pt 9): 2445-2449.
7. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology. 1996; 224 (2): 477-486.
8. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996; 70 (5): 3298-3301.
9. Roden RB, Greenstone HL, Kirnbauer R, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol. 1996; 70 (9): 5875-5883.
10. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347 (21): 1645-1651.
11. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95 (11): 1459-1466.
12. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilloma-virus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367 (9518): 1247-1255.
13. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364 (9447): 1757-1765.
14. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111 (2): 278-285.
15. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369 (9580): 2161-2170.
16. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin. 2007; 3 (4): 109-115.
17. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006; 6 (10): 753-763.
18. Campo MS. Vaccination against papillomavirus in cattle. Curr Top Microbiol Immunol. 1994; 186: 255-266.
19. Chandrachud LM, Grindlay GJ, McGarvie GM, et al. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology. 1995; 211 (1): 204-208.
20. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol. 1996; 77 (pt 7): 1577-1583.
21. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology. 1991; 181 (2): 572-579.
22. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology. 1992; 187 (2): 612-619.
23. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of 12, the minor capsid protein. J Virol. 2002; 76 (19): 9798-9805.
24. Gambhira R, Jagu S, Karanam B, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV16 minor capsid antigen L2. J Virol. 2007; 81 (21): 13927-13931.
25. Alphs HH, Gambhira R, Karanam B, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA. 2008; 105 (15): 5850-5855.
26. Pastrana DV, Gambhira R, Buck CB, et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005; 337 (2): 365-372.
27. Roden RB, Yutzy WI, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000; 270 (2): 254-257.
28. Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoanti-body induction by conjugated papillomavirus virus-like particles. J Immunol. 2002; 169 (11): 6120-6126.
29. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997; 15: 235-270.
30. Dintzis HM, Dintzis RZ, Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci USA. 1976; 73 (10): 3671-3675.
31. Dintzis RZ, Vogelstein B, Dintzis HM. Specific cellular stimulation in the primary immune response: experimental test of a quantized model. Proc Natl Acad Sci USA. 1982; 79 (3): 884-888.
32. Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004; 321 (2): 205-216.
33. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev. 2005; 14 (1): 283-288.
34. Gambhira R, Karanam B, Jagu S, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol. 2007; 81 (24): 13927-13931.
35. Campo MS, Jarrett WF. Vaccination against cutaneous and mucosal papillomavirus in cattle. Ciba Found Symp. 1994; 187: 61-73.
36. Roden RB, Weissinger EM, Henderson DW, et al. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol. 1994; 68 (11): 7570-7574.
37. Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papilloma-virus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA. 2006; 103 (5): 1522-1527.
38. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT. Mechanisms of human papillomavirus type 16 neutralization by 12 cross-neutralizing and 11 type-specific antibodies. J Virol. 2008; 82 (9): 4638-4646.
39. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324 (1): 17-27.
40. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007; 13 (7): 857-861.
41. Marciani DJ, Press JB, Reynolds RC, et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000; 18 (27): 3141-3151.
42. Halperin SA, Dobson S, McNeil S, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine. 2006; 24 (1): 20-26.
43. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 2003; 21 (19-20): 2461-2467.
44. Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD. Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine. 2003; 21 (25-26): 3961-3971.
45. Slovin SF, Ragupathi G, Fernandez C, et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005; 23 (24): 3114-3122.
46. Karanam B, Gambhira R, Peng S, et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine. 2009; 27 (7): 1040-1049.
47. Palmer KE, Benko A, Doucette SA, et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine. 2006; 24 (26): 5516-5525.
48. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol. 1999; 73 (7): 6188-6190.
49. Kawana K, Kawana Y, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine. 2001; 19 (11-12): 1496-1502.
50. Kawana K, Matsumoto K, Yoshikawa H, et al. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology. 1998; 245 (2): 353-359.
51. Kawana K, Yasugi T, Kanda T, et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine. 2003; 21 (27-30): 4256-4260.
52. Laniosz V, Nguyen KC, Meneses PI. Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18. J Virol. 2007; 81 (14): 7435-7448.
53. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001; 93 (4): 284-292.
54. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res. 2006; 66 (23): 11120-11124.
55. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008; 453 (7198): 1122-1126.
56. Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D. 2008; 9 (3): 137-145.
57. McGarvie GM, Chandrachud L, Gaukroger JM, et al. Vaccination of cattle with L2 protein prevents BPV-4 infection. In: Stanley MA, eds. Immunology of Human Papillomaviruses. New York, NY: Plenum Press; 1994: 283-290.
58. Brown DR, Group FIIS. Quadrivalent HPV (Type 6, 11, 16, 18) L1 VLP vaccine: second (FINAL) analysis of cross-protection against CIN/AIS caused by oncogenic HPV types in addition to 16/18. In: 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
59. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118 (12): 3030-3044.
60. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006; 24 (suppl 3): S11-S25.